525 related articles for article (PubMed ID: 18249172)
1. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis.
Biddinger SB; Hernandez-Ono A; Rask-Madsen C; Haas JT; Alemán JO; Suzuki R; Scapa EF; Agarwal C; Carey MC; Stephanopoulos G; Cohen DE; King GL; Ginsberg HN; Kahn CR
Cell Metab; 2008 Feb; 7(2):125-34. PubMed ID: 18249172
[TBL] [Abstract][Full Text] [Related]
2. Sterol carrier protein-2 deficiency attenuates diet-induced dyslipidemia and atherosclerosis in mice.
He H; Wang J; Yannie PJ; Kakiyama G; Korzun WJ; Ghosh S
J Biol Chem; 2018 Jun; 293(24):9223-9231. PubMed ID: 29700117
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of Diabetic Dyslipidemia.
Hirano T
J Atheroscler Thromb; 2018 Sep; 25(9):771-782. PubMed ID: 29998913
[TBL] [Abstract][Full Text] [Related]
4. Lipid and lipoprotein dysregulation in insulin resistant states.
Avramoglu RK; Basciano H; Adeli K
Clin Chim Acta; 2006 Jun; 368(1-2):1-19. PubMed ID: 16480697
[TBL] [Abstract][Full Text] [Related]
5. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.
Han S; Liang CP; Westerterp M; Senokuchi T; Welch CL; Wang Q; Matsumoto M; Accili D; Tall AR
J Clin Invest; 2009 Apr; 119(4):1029-41. PubMed ID: 19273907
[TBL] [Abstract][Full Text] [Related]
6. Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance.
Mulvihill EE; Assini JM; Lee JK; Allister EM; Sutherland BG; Koppes JB; Sawyez CG; Edwards JY; Telford DE; Charbonneau A; St-Pierre P; Marette A; Huff MW
Diabetes; 2011 May; 60(5):1446-57. PubMed ID: 21471511
[TBL] [Abstract][Full Text] [Related]
7. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
8. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome.
Hartvigsen K; Binder CJ; Hansen LF; Rafia A; Juliano J; Hörkkö S; Steinberg D; Palinski W; Witztum JL; Li AC
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):878-85. PubMed ID: 17255537
[TBL] [Abstract][Full Text] [Related]
9. New and emerging regulators of intestinal lipoprotein secretion.
Xiao C; Dash S; Morgantini C; Lewis GF
Atherosclerosis; 2014 Apr; 233(2):608-615. PubMed ID: 24534456
[TBL] [Abstract][Full Text] [Related]
10. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.
Mulvihill EE; Allister EM; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Markle JM; Hegele RA; Huff MW
Diabetes; 2009 Oct; 58(10):2198-210. PubMed ID: 19592617
[TBL] [Abstract][Full Text] [Related]
11. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
Mulvihill EE; Assini JM; Sutherland BG; DiMattia AS; Khami M; Koppes JB; Sawyez CG; Whitman SC; Huff MW
Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):742-8. PubMed ID: 20110573
[TBL] [Abstract][Full Text] [Related]
12. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
13. Myeloid cell-specific ATP-binding cassette transporter A1 deletion has minimal impact on atherogenesis in atherogenic diet-fed low-density lipoprotein receptor knockout mice.
Bi X; Zhu X; Gao C; Shewale S; Cao Q; Liu M; Boudyguina E; Gebre AK; Wilson MD; Brown AL; Parks JS
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1888-99. PubMed ID: 24833800
[TBL] [Abstract][Full Text] [Related]
14. Spontaneously diabetic Ins2(+/Akita):apoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis.
Jun JY; Ma Z; Segar L
Am J Physiol Endocrinol Metab; 2011 Jul; 301(1):E145-54. PubMed ID: 21447785
[TBL] [Abstract][Full Text] [Related]
15. Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis.
Bi X; Zhu X; Duong M; Boudyguina EY; Wilson MD; Gebre AK; Parks JS
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2288-96. PubMed ID: 23814116
[TBL] [Abstract][Full Text] [Related]
16. [Dyslipidemia and atherosclerosis].
Koba S; Hirano T
Nihon Rinsho; 2011 Jan; 69(1):138-43. PubMed ID: 21226274
[TBL] [Abstract][Full Text] [Related]
17. Liver-selective γ-secretase inhibition ameliorates diet-induced hepatic steatosis, dyslipidemia and atherosclerosis.
Kim K; Yu J; Kang JK; Morrow JP; Pajvani UB
Biochem Biophys Res Commun; 2020 Jul; 527(4):979-984. PubMed ID: 32439159
[TBL] [Abstract][Full Text] [Related]
18. Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α.
Lucero D; Miksztowicz V; Macri V; López GH; Friedman S; Berg G; Zago V; Schreier L
Clin Investig Arterioscler; 2015; 27(4):167-74. PubMed ID: 25796423
[TBL] [Abstract][Full Text] [Related]
19. Hepatic insulin receptor deficiency impairs the SREBP-2 response to feeding and statins.
Miao J; Haas JT; Manthena P; Wang Y; Zhao E; Vaitheesvaran B; Kurland IJ; Biddinger SB
J Lipid Res; 2014 Apr; 55(4):659-67. PubMed ID: 24516236
[TBL] [Abstract][Full Text] [Related]
20. GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice.
Taher J; Baker C; Alvares D; Ijaz L; Hussain M; Adeli K
Endocrinology; 2018 Sep; 159(9):3340-3350. PubMed ID: 30052880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
